AUROPHARMA Stock Overview
Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Aurobindo Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,114.50 |
| 52 Week High | ₹1,177.10 |
| 52 Week Low | ₹576.15 |
| Beta | 0.58 |
| 1 Month Change | 12.53% |
| 3 Month Change | -2.98% |
| 1 Year Change | 91.91% |
| 3 Year Change | 12.21% |
| 5 Year Change | 40.09% |
| Change since IPO | 1,564.80% |
Recent News & Updates
Recent updates
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Apr 14Aurobindo Pharma's (NSE:AUROPHARMA) Dividend Will Be ₹1.50
Feb 11Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Jan 08These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well
Nov 27Aurobindo Pharma's (NSE:AUROPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Nov 10Here's Why Shareholders May Want To Be Cautious With Increasing Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Pay Packet
Aug 19Aurobindo Pharma's (NSE:AUROPHARMA) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 15Shareholder Returns
| AUROPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.5% | -2.5% | -2.5% |
| 1Y | 91.9% | 55.2% | 44.5% |
Return vs Industry: AUROPHARMA exceeded the Indian Pharmaceuticals industry which returned 55.2% over the past year.
Return vs Market: AUROPHARMA exceeded the Indian Market which returned 44.5% over the past year.
Price Volatility
| AUROPHARMA volatility | |
|---|---|
| AUROPHARMA Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: AUROPHARMA has not had significant price volatility in the past 3 months.
Volatility Over Time: AUROPHARMA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 23,451 | Kambam Reddy | www.aurobindo.com |
Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and over-the-counter drugs; and active pharmaceutical ingredients (API) for biosimilars, dermatology, respiratory, vaccines, and peptides, as well as oncology, hormones, and sterile products. The company also provides antiretroviral drugs for the people and children living with HIV; and AuroZymes, a biocatalysts product for use in the pharmaceutical and chemical industries.
Aurobindo Pharma Limited Fundamentals Summary
| AUROPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹653.03b |
| Earnings (TTM) | ₹27.70b |
| Revenue (TTM) | ₹278.95b |
23.6x
P/E Ratio2.3x
P/S RatioIs AUROPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AUROPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹278.95b |
| Cost of Revenue | ₹130.37b |
| Gross Profit | ₹148.58b |
| Other Expenses | ₹120.87b |
| Earnings | ₹27.70b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | 47.28 |
| Gross Margin | 53.26% |
| Net Profit Margin | 9.93% |
| Debt/Equity Ratio | 23.6% |
How did AUROPHARMA perform over the long term?
See historical performance and comparison